Vaccine researchers at the biotech firms Bavarian Nordic and Adaptvac are on the right track with their potential vaccine for Covid-19 and a Danish vaccine will most likely enter the market in spring next year.
This is the estimate coming from the University of Copenhagen researcher Ali Salanti, whose research provides the foundations for the ongoing work at Adaptvac, of which he is a board member.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.